With the deepening understanding of the disease mechanisms and the rapid development of novel treatment approaches such as biologics and small-molecule targeted drugs, treatment strategies for ankylosing Spondylitis are undergoing profound transformation. In response to the "Healthy China" initiative and to further enhance the diagnosis and treatment standards of ankylosing Spondylitis in China, as well as to promote the in-depth development of standardized, individualized, and multidisciplinary collaborative management models, the "Expert Seminar on the Standardized Treatment of Ankylosing Spondylitis," organized by the Chengdu High-tech Zone Medical Association, was successfully held online on December 8, 2025.

The seminar aimed to bring together leading experts and frontline clinicians in rheumatology and immunology across China to engage in in-depth exchanges and intellectual discussions on the current status and challenges of ankylosing Spondylitis diagnosis and treatment. Its core objectives included systematically reviewing and interpreting the latest domestic and international guidelines and consensuses, sharing valuable clinical experiences and cutting-edge advancements, and collaboratively exploring solutions for complex cases. By doing so, the seminar sought to promote unified and scientific diagnostic and therapeutic pathways across healthcare institutions at all levels in areas such as early disease recognition, standardized medication, long-term management, and interdisciplinary collaboration. It is expected that this high-level academic dialogue will help bridge regional disparities in clinical practice, improve the overall professional competence of medical practitioners, and ultimately translate the insights gained into tangible benefits that enhance patients' quality of life. Furthermore, the seminar aimed to lay a solid academic foundation for effectively delaying disease progression, reducing disability rates, and supporting patients in returning to normal life and work, thereby contributing to the advancement of rheumatology and immunology in China.